|
||
|
American Journal of Medicine
|
|
|
||
|
American Journal of Medicine
|
The RE-MEDY trial was the first of two trials to compare dabigatran with warfarin for the long term treatment of venous thromboembolism.[9] Patients were enrolled in this trial after initial anticoagulant therapy for 3 to 6 months had been completed, and they were then randomized in a blinded fashion to dabigatran or warfarin (Figure 14). The dose of dabigatran was 150 mg twice a day, the dose of warfarin was determined by the INR, aiming for a target range of 2 to 3. Treatment was continued for up to 36 months and the primary outcomes were VTE and related mortality. Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000.
[9] Schulman S, Kearon C, Kakkar AK, et al; for the RE-MEDY and the RE-SONATE Trials Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-718.